36. Epidermolysis bullosa Clinical trials / Disease details


Clinical trials : 163 Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05157958
(ClinicalTrials.gov)
November 1, 20222/12/2021Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis BullosaDouble Blind, Randomized, Phase II Clinical Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET Versus Vehicle Control in Dystrophic Epidermolysis Bullosa (DEB) PatientsDystrophic Epidermolysis BullosaBiological: ALLO-ASC-SHEET;Other: Vehicle ControlAnterogen Co., Ltd.NULLNot yet recruiting4 Years60 YearsAll6Phase 2NULL
2NCT03752905
(ClinicalTrials.gov)
January 9, 201919/11/2018A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)Recessive Dystrophic Epidermolysis BullosaDrug: PTR-01;Drug: Normal salinePhoenix Tissue Repair, Inc.NULLCompleted16 YearsN/AAll12Phase 1/Phase 2United States
3NCT03183934
(ClinicalTrials.gov)
July 20178/6/2017A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical TrialA Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101Dystrophic Epidermolysis BullosaBiological: ALLO-ASC-DFUAnterogen Co., Ltd.NULLNot yet recruiting2 Years60 YearsAll5Phase 1/2Korea, Republic of